ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ZYBT vs TENX // NET PROFIT MARGIN

Zhengye Biotechnology Holding Limited (Class A) (NASDAQ) VS. Tenax Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ZYBT 3 — TENX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZYBT VS. TENX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ZYBT TENX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 20.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -22.30% -35.00% +12.70 ZYBT /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 2.61% — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -34.80% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.90 0.23 +1.67 ZYBT /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 ZYBT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.1 44.7 -1.60 TENX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $67.8M $69.6M -$1.8M TENX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ZYBT REV TENX REV ZYBT GROSS % TENX GROSS % ZYBT FCF TENX FCF
FY 2025 $16.6M $0 20.5% — $1.8M -$35.8M
FY 2024 $25.5M $0 49.0% — $3.8M -$14.8M
FY 2023 — $0 — — — -$5.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZYBT // BETA —
TENX // BETA —